ClinicalTrials.gg
RecruitingNCT07310433Updated Oct 28, 2026

Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer

A Phase 2 interventional study of Dapagliflozin (10mg Tab) and standard medical care (ADT + NHA) in Prostate Cancer and Metastatic Prostate Cancer, sponsored by Yung NA. Recruiting at 2 sites in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Yung NA · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Oct 28, 2026Now RecruitingSite recruiting status changed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 542 studies in Prostatic Neoplasms with a site in China — 281 open to participants now, 342 under way, 52 of them phase 3. Prostatic Neoplasms · China.

Planned enrollment
259th of 436
68 · median 100
Started
2026
with 82 others
Phase 2
84 of 542
51 open now
Primary completion
2029-04
later than 309 of 341 live
Registered
449th of 542
by date

Among the 542 studies in Prostatic Neoplasms with a site in China, this one is the 259th largest by planned enrollment of the 436 interventional ones that give a count, is one of 83 that started in 2026, is one of 84 in phase 2, reaches primary completion later than 309 of the 341 other live ones, and was the 449th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

281 of the 542 studies in Prostatic Neoplasms with a site in China are open now. Recruiting first, the newest first:

276 more — sign in →

All 281 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 542 studies in Prostatic Neoplasms with a site in China, or all of them as a file.
02

Study summary

Dapagliflozin is a well-established medication being marketed and used for treatment Type 2 diabetes mellitus (T2DM). In retrospective cohort studies done by our team, we found that metastatic prostate cancer patients who received Dapagliflozin together with standard anti-cancer treatment, androgen deprivation therapy (ADT) combined with novel hormonal agent (NHA), had better tumor control than those having ADT and NHA.

Read the detailed description

Androgen deprivation therapy (ADT) combined with novel hormonal agent (NHA) is a standard treatment for metastatic castrate-resistant prostate cancer (mCRPC) but treatment failure and side effects remain significant concerns. Researchers are identifying non-castrating therapies to improve treatment tolerance and quality of life. Recently, the anti-tumor effect of sodium-glucose cotransporter 2 (SGLT2) inhibitors has been revealed in vitro, vivo, and population-based observational studies. However, only one phase I trial has assessed their safety in PCa, and no randomized controlled trial (RCT) has evaluated their efficacy.

A phase 2 multicenter, open-label RCT will be performed in Queen Mary Hospital, Ruijin Hospital and Huashan Hospital (subject to Ethics Committee approval at each center) with 60 mCRPC patients proposed to be recruited. Data will be collected through radiological scan, laboratory test and case report form. Eligible patients will be randomized into two treatment groups with a 1:1 ratio. Patients in the test group will receive dapagliflozin on top of NHA plus ADT while those in the control group will receive standard of care NHA plus ADT. The primary outcome is radiographic progression-free survival. Secondary outcomes include overall survival, biomedical recurrence-free survival, time to first subsequent anti-cancer therapy, time to treatment failure, objective response rate and duration of response. Exploratory outcomes include treatment-related adverse events, quality of life, fear of cancer recurrence, and severity of pain. The primary analysis is efficacy analysis based on the intention-to-treat population. Hazard ratios will be calculated using Cox regression. Interim and finial analyses will be performed upon different study stages.

This study will be the first RCT to evaluate the efficacy and safety of SGLT2 inhibitors combined with the first-line next-generation hormonal agent (NHA) for mCRPC treatment. Given their general tolerability and clinical use, repurposing SGLT2 inhibitors as a non-castrating therapy may lead to better outcomes for PCa patients. Findings of this study will inform a novel combination therapy for advanced PCa, potentially enhancing clinical practice guidelines for its treatment and management in Hong Kong and mainland China

03

Conditions studied

  • Prostate Cancer
  • Metastatic Prostate Cancer

Browse trials for

Keywords

  • prostate cancer
  • sglt2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of 18 years and above
  • or cytologically confirmed diagnosis of prostatic adenocarcinoma without neuroendocrine/ small cell histology;
  • PCa progression while receiving ADT (or post bilateral orchiectomy) within 6 months before screening: two consecutive rising PSA levels, radiographic soft tissue or bone progression;
  • Current evidence of disease by radiological scan;
  • Decided to receive any of the NHA (including Abiraterone Acetate, Enzalutamide, Apalutamide or Darolutamide) under standard of care setting, or started NHA for no more than 28 days at the time of treatment period start;
  • Ongoing androgen deprivation with serum testosterone \<50 ng/dL (\<1.7 nM);
  • Naïve of taxane-based chemotherapy regimens;
  • (ECOG) performance status ≤ 1;
  • Normal hematologic and organ function as defined below: (a) leukocytes ≥ 3,000/mcL; (b) ≥ 1,500/mcL; (c) ≥ 100,000/mcL; (d) total ≤ 1.5 x institutional (IULN); (e) (SGOT)/ALT(SGPT) ≤ 3.0 x IULN; (f) estimated eGFR ≥ 30 mL/min/1.73m2;
  • Ability to understand and willingness to sign an IRB-approved written document.

Exclusion criteria

Exclusion Criteria:

  • Current or previous treatment with SGLT2 inhibitors or thiazolidinedione;
  • Presence of type 1 diabetes mellitus, insulin-requiring diabetes mellitus or poorly controlled diabetes mellitus (i.e., > 10%, unless approved by endocrinologist);
  • Presence of other than prostate cancer within two years prior to study enrollment;
  • Disease progressed during or after treatment with one NHA;
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to dapagliflozin;
  • abnormal serum potassium or sodium level;
  • Presence of uncontrolled comorbidities including but not limited to ongoing or active infection (e.g., , , and tuberculosis), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, peripheral arterial disease, ketoacidosis, severe kidney disease, symptomatic hypotension, and chronic/frequent urinary tract infections or yeast infections;
  • Participation in another clinical trial with therapeutic intent within 28 days prior to enrollment;
  • Inability to swallow capsules/tablets
  • Any medical conditions that might deem unsafe or for inclusion in the clinical trial, per investigator's discretion
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
68 participants (estimated)

Study arms

  • Experimental
    Intervention

    dapagliflozin 10 mg daily along with standard medical care (NHA + ADT)

    Drug: Dapagliflozin (10mg Tab) · Drug: standard medical care (ADT + NHA)

  • Active comparator
    Control

    Standard of Care (ADT + NHA)

    Drug: standard medical care (ADT + NHA)

Interventions

  • DrugDapagliflozinStudies of DapagliflozinDapagliflozin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dapagliflozin (10mg Tab)

  • Drugstandard medical care (ADT + NHA)

    standard medical care for metastatic prostate cancer (ADT + NHA), the choice of NHA and ADT to be agreed among participant and treating physician with dosage and frequency according to local guideline. Surgical castration is also acceptable as ADT.

06

What researchers measure

Primary outcomes

  1. Radiographic Progression-Free Survival (rPFS)

    Radiographic progression-free survival is defined as the time from randomization to radiographic disease progression or death from any cause, whichever occurs first. Radiographic progression is assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for soft-tissue lesions and standard criteria for bone metastases. Participants without documented radiographic progression or death will be censored at the date of their last radiographic assessment showing no progression.

    Time frame: From randomization to radiographic disease progression or death from any cause, whichever occurs first, assessed up to 60 months.

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival is defined as the time from randomization to death from any cause.

    Time frame: From randomization to death from any cause, assessed up to 60 months.

  2. Biochemical Recurrence-Free Survival (bRFS)

    Biochemical recurrence-free survival is defined as the time from randomization to biochemical recurrence. Biochemical recurrence is defined as an increase in prostate-specific antigen (PSA) of at least 25% and an absolute increase of at least 2 ng/mL above the nadir, confirmed by a repeat PSA measurement obtained at least 3 weeks later. PSA is assessed every 12 weeks (±2 weeks), with an additional measurement to confirm suspected biochemical recurrence.

    Time frame: From randomization to biochemical recurrence, assessed up to 60 months.

  3. Time to First Subsequent Anticancer Therapy (TFST)

    Time to first subsequent anticancer therapy is defined as the time from randomization to initiation of the first subsequent anticancer therapy or death from any cause, whichever occurs first.

    Time frame: From randomization to initiation of the first subsequent anticancer therapy or death from any cause, whichever occurs first, assessed up to 60 months.

  4. Time to Treatment Failure (TTF)

    Time to treatment failure is defined as the time from randomization to permanent discontinuation of the next-generation hormonal agent (NHA) and/or dapagliflozin due to disease progression, toxicity, or death.

    Time frame: From randomization to treatment failure, assessed up to 60 months.

  5. Objective Response Rate (ORR)

    Objective response rate is defined as the percentage of participants with measurable disease who achieve a complete response or partial response according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

    Time frame: From randomization to radiographic disease progression, assessed up to 60 months.

  6. Duration of Response (DOR)

    Duration of response is evaluated in participants who achieve a complete response or partial response according to RECIST version 1.1.

    Time frame: From the date of first documented complete or partial response to radiographic disease progression or death from any cause, whichever occurs first, assessed up to 60 months.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the findings reported in publications arising from this trial will be made available upon reasonable request, subject to applicable legal and ethical requirements.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Apr 2029, 35 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 35 months is below that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 28, 2026: start Jun 2026 → May 2026, primary completion Oct 2029 → Apr 2029 and completion Oct 2030 → Apr 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2025
First posted
Dec 30, 2025
StartActual
May 1, 2026was Jun 2026
Primary completionEst.
Apr 30, 2029was Oct 2029
CompletionEst.
Apr 30, 2030was Oct 2030
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 28, 2026
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • Huashan Hospital · Shanghai, Chinano status→Recruiting
  • Ruijin Hospital · Shanghai, Chinano status→Recruiting
Oct 28, 2026
Start date
Jun 1, 2026→May 1, 2026 (actual)
Oct 28, 2026
Primary completion
Oct 30, 2029→Apr 30, 2029
Oct 28, 2026
Study completion
Oct 30, 2030→Apr 30, 2030
Oct 28, 2026
Enrollment
60→68
Oct 28, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedRadiographic Progression free survival-Free Survival (rPFS)Time frame: From date of randomization until the date of first disease progression per RECIST 1.1 criteria, assessed up to 60 months → From randomization to radiographic disease progression or death from any cause, whichever occurs first, assessed up to 60 months.
Oct 28, 2026
Secondary outcomes
2 edited, 4 added, 1 removed
What changed in the outcomes
  • EditedOverall survivalSurvival (OS)Time frame: From date of randomization until the date of date of death from any cause, assessed up to 60 months → From randomization to death from any cause, assessed up to 60 months.
  • EditedDuration of responseResponse (DOR)Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months. → From the date of first documented complete or partial response to radiographic disease progression or death from any cause, whichever occurs first, assessed up to 60 months.
  • AddedBiochemical Recurrence-Free Survival (bRFS)Time frame: From randomization to biochemical recurrence, assessed up to 60 months.
  • AddedTime to First Subsequent Anticancer Therapy (TFST)Time frame: From randomization to initiation of the first subsequent anticancer therapy or death from any cause, whichever occurs first, assessed up to 60 months.
  • AddedTime to Treatment Failure (TTF)Time frame: From randomization to treatment failure, assessed up to 60 months.
  • AddedObjective Response Rate (ORR)Time frame: From randomization to radiographic disease progression, assessed up to 60 months.
  • RemovedAdverse EventTime frame: All adverse events will be evaluated once every 3 months since the date of randomization, until 1 year after the end of treatment, or resolution of any treatment related adverse event, whichever is later.
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Not yet recruiting→Recruiting
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • Huashan Hospital · Shanghai, Chinano status→Recruiting
    • Ruijin Hospital · Shanghai, Chinano status→Recruiting
    Start date Jun 1, 2026→May 1, 2026 (now actual)
    Primary completion Oct 30, 2029→Apr 30, 2029
    Study completion Oct 30, 2030→Apr 30, 2030
    Enrollment 60→68
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedRadiographic Progression free survival-Free Survival (rPFS)Time frame: From date of randomization until the date of first disease progression per RECIST 1.1 criteria, assessed up to 60 months → From randomization to radiographic disease progression or death from any cause, whichever occurs first, assessed up to 60 months.
    Secondary outcomes 2 edited, 4 added, 1 removed
    What changed in the outcomes
    • EditedOverall survivalSurvival (OS)Time frame: From date of randomization until the date of date of death from any cause, assessed up to 60 months → From randomization to death from any cause, assessed up to 60 months.
    • EditedDuration of responseResponse (DOR)Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 60 months. → From the date of first documented complete or partial response to radiographic disease progression or death from any cause, whichever occurs first, assessed up to 60 months.
    • AddedBiochemical Recurrence-Free Survival (bRFS)Time frame: From randomization to biochemical recurrence, assessed up to 60 months.
    • AddedTime to First Subsequent Anticancer Therapy (TFST)Time frame: From randomization to initiation of the first subsequent anticancer therapy or death from any cause, whichever occurs first, assessed up to 60 months.
    • AddedTime to Treatment Failure (TTF)Time frame: From randomization to treatment failure, assessed up to 60 months.
    • AddedObjective Response Rate (ORR)Time frame: From randomization to radiographic disease progression, assessed up to 60 months.
    • RemovedAdverse EventTime frame: All adverse events will be evaluated once every 3 months since the date of randomization, until 1 year after the end of treatment, or resolution of any treatment related adverse event, whichever is later.
    + 2 other changes: verification date and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07310433
Lead sponsor
Yung NA
Responsible party
Yung NA (Clinical Assistant Professor, The University of Hong Kong) — Sponsor-investigator
First posted
Dec 30, 2025
Start date
May 1, 2026
Primary completion
Apr 30, 2029 (estimated)
Completion
Apr 30, 2030 (estimated)
Last update
Oct 28, 2026

Study contacts

Study Coordinator
Contact
stac@hku.hk
852-22554852
Yung Na, BM, MD, MPH
principal investigator · The University of Hong Kong

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion